Rozrolimupab: Final Phase II data

Previously reported data from a dose-escalation, open-label, international Phase II trial of rozrolimupab in 61 RhD-positive, non-splenectomized patients with ITP

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE